These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
248 related articles for article (PubMed ID: 18466427)
1. Prevention of CMV disease in pediatric kidney transplant recipients: evaluation of pp67 NASBA-based pre-emptive ganciclovir therapy combined with CMV hyperimmune globulin prophylaxis in high-risk patients. Renoult E; Clermont MJ; Phan V; Buteau C; Alfieri C; Tapiero B Pediatr Transplant; 2008 Jun; 12(4):420-5. PubMed ID: 18466427 [TBL] [Abstract][Full Text] [Related]
2. [Effectiveness of preemptive therapy with ganciclovir in recipients of renal transplants at high risk (R-/D+) for the development of cytomegalovirus disease]. Aranda-Verástegui F; Alberú J; Soto-Ramírez LE; González-Aguirre H; Muñoz Trejo T; Mancilla E; Díliz H; Correa-Rotter R; Sierra-Madero J Rev Invest Clin; 2002; 54(3):198-203. PubMed ID: 12183888 [TBL] [Abstract][Full Text] [Related]
3. Early ganciclovir therapy effectively controls viremia and avoids the need for cytomegalovirus (CMV) prophylaxis in renal transplant patients with cytomegalovirus antigenemia. Gotti E; Suter F; Baruzzo S; Perani V; Moioli F; Remuzzi G Clin Transplant; 1996 Dec; 10(6 Pt 1):550-5. PubMed ID: 8996777 [TBL] [Abstract][Full Text] [Related]
4. Comparison of intravenous ganciclovir and cytomegalovirus hyperimmune globulin pre-emptive treatment in cytomegalovirus-positive heart transplant recipients. Vrtovec B; Thomas CD; Radovancevic R; Frazier OH; Radovancevic B J Heart Lung Transplant; 2004 Apr; 23(4):461-5. PubMed ID: 15063406 [TBL] [Abstract][Full Text] [Related]
5. Cytomegalovirus prophylaxis with ganciclovir in kidney transplant recipients receiving induction antilymphocyte antibodies. Said T; Nampoory MR; Johny KV; Pacsa AS; Mini Abraham P; Nair MP; Abdel-Haleem M; Samhan M; Al-Mousawi M Transplant Proc; 2004; 36(6):1847-9. PubMed ID: 15350495 [TBL] [Abstract][Full Text] [Related]
6. Late cytomegalovirus infection after oral ganciclovir prophylaxis in renal transplant recipients. Murray BM; Subramaniam S Transpl Infect Dis; 2004 Mar; 6(1):3-9. PubMed ID: 15225220 [TBL] [Abstract][Full Text] [Related]
7. High-dose acyclovir and pre-emptive ganciclovir in prevention of cytomegalovirus disease in pediatric patients following peripheral blood stem cell transplantation. Hazar V; Kansoy S; Küpesiz A; Aksoylar S; Kantar M; Yeşilipek A Bone Marrow Transplant; 2004 May; 33(9):931-5. PubMed ID: 15034541 [TBL] [Abstract][Full Text] [Related]
9. Long-term outcomes of cytomegalovirus infection and disease after lung or heart-lung transplantation with a delayed ganciclovir regimen. Thomas LD; Milstone AP; Miller GG; Loyd JE; Stephen Dummer J Clin Transplant; 2009; 23(4):476-83. PubMed ID: 19453645 [TBL] [Abstract][Full Text] [Related]
10. HCMV pp67-mRNA detection by nucleic acid sequence-based amplification in renal transplant patients. Merlino C; Bergallo M; Gregori G; Sinesi F; Bollero C; Cavallo R New Microbiol; 2002 Jan; 25(1):1-8. PubMed ID: 11837384 [TBL] [Abstract][Full Text] [Related]
11. Evaluation of the NucliSens CMV pp67 assay for detection and monitoring of human cytomegalovirus infection after allogeneic stem cell transplantation. Hebart H; Rudolph T; Loeffler J; Middeldorp J; Ljubicic T; Jahn G; Einsele H Bone Marrow Transplant; 2002 Aug; 30(3):181-7. PubMed ID: 12189537 [TBL] [Abstract][Full Text] [Related]
12. A hybrid strategy for the prevention of cytomegalovirus-related complications in pediatric liver transplantation recipients. Madan RP; Campbell AL; Shust GF; Kahn AR; Wistinghausen B; Posada R; Kerkar N; Shneider BL; Emre S; Herold BC Transplantation; 2009 May; 87(9):1318-24. PubMed ID: 19424031 [TBL] [Abstract][Full Text] [Related]
13. [pp65 antigenemia in evaluation of cytomegalovirus infection after kidney transplantation]. Orlić P; Dvornik S; Husnjak SC; Aralica M; Orlić L; Zivcić-Cosić S; Sladoje-Martinović B; Fućak M Acta Med Croatica; 2003; 57(1):49-52. PubMed ID: 12876863 [TBL] [Abstract][Full Text] [Related]
14. A randomized prospective trial of oral versus intravenous ganciclovir for prophylaxis of cytomegalovirus infection and disease in high-risk kidney recipients. Nafar M; Pezeshki ML; Farrokhi F; Einollahi B; Pour-Reza-Gholi F; Firouzan A; Farhangi S Transplant Proc; 2005 Sep; 37(7):3053-5. PubMed ID: 16213302 [TBL] [Abstract][Full Text] [Related]